ESLA vs. BCLI, CYTH, TARA, OKYO, SABS, INAB, NKGN, CRTX, DYAI, and ACHL
Should you be buying Estrella Immunopharma stock or one of its competitors? The main competitors of Estrella Immunopharma include Brainstorm Cell Therapeutics (BCLI), Cyclo Therapeutics (CYTH), Protara Therapeutics (TARA), OKYO Pharma (OKYO), SAB Biotherapeutics (SABS), IN8bio (INAB), NKGen Biotech (NKGN), Cortexyme (CRTX), Dyadic International (DYAI), and Achilles Therapeutics (ACHL). These companies are all part of the "medical" sector.
Estrella Immunopharma (NASDAQ:ESLA) and Brainstorm Cell Therapeutics (NASDAQ:BCLI) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, analyst recommendations, risk, valuation, community ranking and media sentiment.
In the previous week, Brainstorm Cell Therapeutics had 1 more articles in the media than Estrella Immunopharma. MarketBeat recorded 2 mentions for Brainstorm Cell Therapeutics and 1 mentions for Estrella Immunopharma. Estrella Immunopharma's average media sentiment score of 1.00 beat Brainstorm Cell Therapeutics' score of -0.50 indicating that Estrella Immunopharma is being referred to more favorably in the media.
Brainstorm Cell Therapeutics received 290 more outperform votes than Estrella Immunopharma when rated by MarketBeat users.
Brainstorm Cell Therapeutics' return on equity of 0.00% beat Estrella Immunopharma's return on equity.
Estrella Immunopharma has a beta of 0.12, indicating that its stock price is 88% less volatile than the S&P 500. Comparatively, Brainstorm Cell Therapeutics has a beta of 0.28, indicating that its stock price is 72% less volatile than the S&P 500.
0.4% of Estrella Immunopharma shares are owned by institutional investors. Comparatively, 14.3% of Brainstorm Cell Therapeutics shares are owned by institutional investors. 55.1% of Estrella Immunopharma shares are owned by insiders. Comparatively, 5.5% of Brainstorm Cell Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Summary
Brainstorm Cell Therapeutics beats Estrella Immunopharma on 5 of the 9 factors compared between the two stocks.
Get Estrella Immunopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for ESLA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ESLA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Estrella Immunopharma Competitors List
Related Companies and Tools
